0000950170-24-005562.txt : 20240118 0000950170-24-005562.hdr.sgml : 20240118 20240118200006 ACCESSION NUMBER: 0000950170-24-005562 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240118 FILED AS OF DATE: 20240118 DATE AS OF CHANGE: 20240118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buell Jennifer CENTRAL INDEX KEY: 0001711184 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 24543426 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4 1 ownership.xml 4 X0508 4 2024-01-18 0001840229 MiNK Therapeutics, Inc. INKT 0001711184 Buell Jennifer 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 false true false false Chief Executive Officer false Stock Option 0.87 2024-01-16 4 A false 500000 0.00 A 2034-01-16 Common Stock 500000 500000 D Stock Option 0.87 2024-01-16 4 A false 660919 0.00 A 2034-01-16 Common Stock 660919 660919 D An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 for her performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024 By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell 2024-01-18